NCT03917550

Brief Summary

To investigate the efficacy and acceptability of a guided internet delivered transdiagnostic intervention, targeting mild to moderate clinical symptoms of anxiety and depression and emphasizing the changes taking place at the level of the structures of the self.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
260

participants targeted

Target at P75+ for not_applicable depression

Timeline
Completed

Started Mar 2019

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 18, 2019

Completed
27 days until next milestone

First Submitted

Initial submission to the registry

April 14, 2019

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 17, 2019

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 30, 2019

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 27, 2020

Completed
Last Updated

April 17, 2019

Status Verified

April 1, 2019

Enrollment Period

6 months

First QC Date

April 14, 2019

Last Update Submit

April 14, 2019

Conditions

Keywords

TransdiagnosticCognitive behavioural therapy (CBT)DepressionAnxiety

Outcome Measures

Primary Outcomes (4)

  • Patient Health Questionnaire 9 (PHQ9)

    The Patient Health Questionnaire 9 (PHQ9) was designed to measure participant's level of depression. The scale is unidimensional and the total score ranges from 0 to 27. Low scores are associated with low levels of depression, while high scores are associated with high levels of depression.

    Absolute values (average score) of PHQ9 at 10 weeks (post-intervention)

  • Generalized Anxiety Disorder 7 (GAD7)

    Generalized Anxiety Disorder 7 (GAD7) was designed to measure participant's level of generalized anxiety or worry. The scale is unidimensional and the total score ranges from 0 to 21. Low scores are associated with low levels of worry, while high scores are associated with high levels of worry.

    Absolute values (average score) of GAD7 at 10 weeks (post-intervention)

  • Social Phobia Inventory (SPIN)

    The SPIN was designed to measure participant's level of social phobia. The scale is unidimensional and the total score ranges from 0 to 68. Low scores are associated with low levels of social phobia, while high scores are associated with high levels of social phobia.

    Absolute values (average score) of SPIN at 10 weeks (post-intervention)

  • Panic Disorder Severity Scale-Self Report (PDSS-SR)

    The PDSS-SR was designed to measure participant's level of panic. The scale is unidimensional and the total score rages from 0 to 28. Low scores are associated with low levels of panic, while high scores are associated with high levels of panic.

    Absolute values (average score) of PDSS-SR at 10 weeks (post-intervention)

Secondary Outcomes (13)

  • Work and Social Adjustment Scale (WSAS)

    Absolute values (average score) of WSAS at 10 weeks (post-intervention)

  • Beck Depression Inventory-II (BDI-II)

    Absolute values (average score) of BDI-II at 10 weeks (post-intervention)

  • Penn State Worry Questionnaire (PSWQ)

    Absolute values (average score) of PSWQ at 10 weeks (post-intervention)

  • Anxiety Sensitivity Index 16 (ASI16)

    Absolute values (average score) of ASI at 10 weeks (post-intervention)

  • Self-Concept Clarity Scale (SCCS)

    Absolute values (average score) of SCCS at 10 weeks (post-intervention)

  • +8 more secondary outcomes

Study Arms (2)

Recovery (Transdiagnostic & self)

EXPERIMENTAL

A longitudinal study conducted before has shown that self-compassion, unconditional self-acceptance, self-esteem and self concept clarity could be considered risk factors for the severity of the clinical symptoms in anxiety and depression. This is the main reason why this arm consists of the Transdiagnostic intervention program for emotional disorders plus a number of intervention techniques targeting the self-concepts mentioned before. The intervention, based on the Cognitive Behavioral Therapy (CBT) principles, is designed to encourage participants to confront and experience uncomfortable emotions, and use adaptive coping mechanisms. Moreover, additional intervention techniques targeting self-concepts will be used to improve participants' self.

Behavioral: Recovery (Transdiagnostic & self)

Transdiagnostic

ACTIVE COMPARATOR

This arm represents the Transdiagnostic intervention program for emotional disorders. The intervention, based on the Cognitive Behavioral Therapy (CBT) principles, is designed to encourage participants to confront and experience uncomfortable emotions, and use adaptive coping mechanisms.

Behavioral: Transdiagnostic

Interventions

This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors. In addition, specific intervention designed to improve self-compassion, unconditional self-acceptance, self-esteem and self concept clarity were added.

Recovery (Transdiagnostic & self)
TransdiagnosticBEHAVIORAL

This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors.

Transdiagnostic

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • be fluent in Romanian,
  • be at least 18 years of age,
  • have at least a clinical diagnosis of major depressive disorder/dysthymia, and/or generalized anxiety disorder, and/or social anxiety disorder, panic anxiety disorder and/or Agoraphobia, specific phobia or any combination of these conditions on Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders 5 (SCID-I 5)

You may not qualify if:

  • suicidal plans,
  • changes in the dosage if psychotropic medication during the last month (if present),
  • have bipolar disorder or psychosis (according to medication status),
  • have an alcohol/substance abuse and/or dependence disorder,
  • currently take part in other psychological treatment,
  • obvious obstacle to participation (i.e., no current Internet access, long travel plans during the treatment period etc.)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

West University of Timisoara

Timișoara, Timiș County, 300223, Romania

RECRUITING

Related Publications (1)

  • Isbasoiu AB, Tulbure BT, Rusu A, Sava FA. Can We Boost Treatment Adherence to an Online Transdiagnostic Intervention by Adding Self-Enhancement Strategies? Results From a Randomized Controlled Non-inferiority Trial. Front Psychol. 2021 Dec 2;12:752249. doi: 10.3389/fpsyg.2021.752249. eCollection 2021.

Related Links

MeSH Terms

Conditions

DepressionDysthymic DisorderPanic DisorderPhobia, SocialGeneralized Anxiety DisorderPhobia, SpecificAnxiety Disorders

Interventions

Salvage Therapy

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehaviorDepressive DisorderMood DisordersMental DisordersPhobic Disorders

Intervention Hierarchy (Ancestors)

Therapeutics

Study Officials

  • Andreea Isbasoiu, PhD student

    West University of Timisoara

    STUDY DIRECTOR

Central Study Contacts

Bogdan Tudor Tulbure, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Folow-up interviews will be carried out by a different team of assessors (blinded to the treatment condition)
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 14, 2019

First Posted

April 17, 2019

Study Start

March 18, 2019

Primary Completion

August 30, 2019

Study Completion

March 27, 2020

Last Updated

April 17, 2019

Record last verified: 2019-04

Data Sharing

IPD Sharing
Will not share

Data will be process only at the group level. No individual data will be shared to third parties.

Locations